Aimmune Therapeutics Inc. (AIMT) Trading 4.8% Higher
Aimmune Therapeutics Inc. (NASDAQ:AIMT) shares traded up 4.8% during mid-day trading on Monday . The stock traded as high as $13.59 and last traded at $13.50, with a volume of 53,211 shares traded. The stock had previously closed at $12.88.
Several research firms have recently commented on AIMT. Zacks Investment Research downgraded Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a research note on Wednesday, August 10th. Piper Jaffray Cos. reaffirmed an “overweight” rating and issued a $38.00 price objective on shares of Aimmune Therapeutics in a research note on Wednesday, June 29th. Finally, Bank of America Corp. reaffirmed a “buy” rating on shares of Aimmune Therapeutics in a research note on Monday, May 16th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $33.40.
The firm’s market cap is $561.98 million. The stock’s 50 day moving average is $11.54 and its 200 day moving average is $13.82.
Aimmune Therapeutics (NASDAQ:AIMT) last announced its earnings results on Wednesday, August 10th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. On average, analysts forecast that Aimmune Therapeutics Inc. will post ($1.71) earnings per share for the current fiscal year.
In related news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction dated Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.
An institutional investor recently raised its position in Aimmune Therapeutics stock. RS Investment Management Co. LLC raised its stake in shares of Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 12.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 804,143 shares of the company’s stock after buying an additional 88,180 shares during the period. RS Investment Management Co. LLC owned approximately 1.90% of Aimmune Therapeutics worth $14,836,000 at the end of the most recent quarter.
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.